Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Recombinant mumps virus jeryl lynn 2 based vaccine

A mumps virus and genome technology, applied in the field of new vaccines against mumps, can solve problems such as difficulty in further developing vaccines

Inactive Publication Date: 2018-02-06
CADILA HEALTHCARE LTD
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] It is well understood from the above disclosure that further vaccine development is difficult by rescue model development of the JL2 strain approaching Vero cells or CEF as host cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant mumps virus jeryl lynn 2 based vaccine
  • Recombinant mumps virus jeryl lynn 2 based vaccine
  • Recombinant mumps virus jeryl lynn 2 based vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0110] Example 1: Construction of the clone of the full-length DNA genome of the attenuated JL2 strain of mumps virus Production of whole mumps JL2 long cDNA

[0111] Six genome sequence fragments were chemically synthesized (GeneArt-Thermo Fisher Scientific) to cover the total genome length of mumps virus (15,384 bp). Subsequently, each genome fragment and vector was cleaved by specific restriction endonucleases (NewEngland Bio Labs) and cloned into an intermediate vector. through such as figure 1 Each fragment was verified by its separation on an agarose gel as indicated. Fragments obtained after restriction digestion have been described as follows:

[0112] Fragment 1: NotI-RsrII at positions 1 to 3576 (SEQ ID NO.1);

[0113] Fragment 2: RsrII-AvrII at positions 3576 to 6258 (SEQ ID NO.2);

[0114] Fragment 3: AvrII-XhoI at positions 6258 to 8438 (SEQ ID NO.3);

[0115] Fragment 4: XhoI-KpnI at positions 8438 to 10498 (SEQ ID NO.4);

[0116] Fragment 5: KpnI-XmaI ...

Embodiment 2

[0121] Example 2: Rescue of attenuated mumps Jeryl-Lynn 2 virus

[0122] by pMuV JL2 with helper plasmid p_NJL2 , p_p JL2 , p_L JL2 Commercially available HEK 293T cells were transfected together with pSC6-T7. HEK 293T cells were seeded into 35 mm wells to reach ~50-70% confluency when transfected. Confluency is a term commonly used as an estimate of the number of adherent cells in a dish or flask, referring to the proportion of the surface covered by a monolayer of cells. Four hours before transfection, replace the medium with 3 ml DMEM containing 10% FCS. All recombinant plasmids were prepared according to the QIAGEN plasmid preparation kit. Ca for DNA 2+ The kit for phosphate co-precipitation was from Invitrogen.

[0123] Cells were co-transfected with the plasmids at the following final concentrations:

[0124]

[0125] Add the mentioned plasmids diluted in HO to the 2 Add the mixture to another Eppendorf tube containing HEPES buffer with shaking and incubate a...

Embodiment 3

[0133] Example 3: Amplification of Rescued Mumps JL2 Virus

[0134] Rescued rMuV JL2 The P0 generation of FL virus was propagated in WHO-approved Vero cells. Vero cells were maintained as a monolayer in DMEM supplemented with 5% FBS, and when confluency reached 70-80%, rescued rMuV had been passaged using 0.5-1.0 mL of rescued virus in a total volume of 5.0 mL of OPTIMEM. JL2 The P0 passage of FL virus infects Vero cells. Incubate the cells at 37 °C and 5% CO 2 Incubate for 1 hour. After incubation, the inoculum was replaced with DMEM+5% FBS. Infected cells were split after 2 days, and 90-100% syncytia formation was observed after 5 days of infection (5-dpi). Cell-free (CF) and cell-associated (CA) fractions have been collected to obtain laboratory-scale virus stocks up to 1 × 10 in the collected cell-free fraction (CF). 4 pfu / mL to 1×10 in the collected cell-associated fraction (CA) 6 Titers in pfu / mL.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a novel vaccine against mumps composed of highly immunogenic rMuVJL2 (recombinant mumps virus Jeryl Lynn2 based). Further, method to develop said immunogenic compositionis described in the present invention. The vaccine according to the present invention is safe, cost effective, highly efficacious and stable and consistent in terms of productivity.

Description

technical field [0001] The present invention provides highly immunogenic rMuV JL2 Constituted new vaccine against mumps (based on recombinant mumps virus Jeryl Lynn2). Furthermore, methods for developing said immunogenic compositions are described in the present invention. The vaccine according to the present invention is safe, cost-effective, highly effective and stable and consistent in terms of productivity. Background technique [0002] Mumps is an acute viral disease characterized by fever and swelling of the parotid glands, which usually affects young children and can lead to complications such as orchitis, oophoritis, pancreatitis and meningoencephalitis. However, typical disease develops in about half of infected individuals. Mumps virus (MuV), a member of the paramyxoviridae family, subfamily Paramyxovirinae, and genus Rubulavirus, infects only humans [Hviid et al., 2008] . MuV has a single-stranded negative-sense RNA genome consisting of 15,384 nucleotides. T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/45C12N15/86C12N5/10C07K14/12A61K39/165A61P31/14
CPCA61K39/12C07K14/005C12N7/00A61K2039/5254C12N2760/18743C12N2760/18761C12N2760/18751C12N2760/18734C12N2760/18721C12N2760/18722C12N7/04A61P27/16A61P31/14A61P37/04
Inventor 赖因哈德·格吕克维维亚娜·詹尼诺戈拉夫·古普塔
Owner CADILA HEALTHCARE LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com